HRP20180115T1 - Laktoferin za uporabu u dijagnozi ili prognozi alzheimerove bolesti - Google Patents
Laktoferin za uporabu u dijagnozi ili prognozi alzheimerove bolesti Download PDFInfo
- Publication number
- HRP20180115T1 HRP20180115T1 HRP20180115TT HRP20180115T HRP20180115T1 HR P20180115 T1 HRP20180115 T1 HR P20180115T1 HR P20180115T T HRP20180115T T HR P20180115TT HR P20180115 T HRP20180115 T HR P20180115T HR P20180115 T1 HRP20180115 T1 HR P20180115T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- alzheimer
- subject
- lactoferrin
- level
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims 9
- 102000010445 Lactoferrin Human genes 0.000 title claims 6
- 108010063045 Lactoferrin Proteins 0.000 title claims 6
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims 6
- 229940078795 lactoferrin Drugs 0.000 title claims 6
- 235000021242 lactoferrin Nutrition 0.000 title claims 6
- 238000004393 prognosis Methods 0.000 title claims 4
- 238000003745 diagnosis Methods 0.000 title claims 3
- 238000000034 method Methods 0.000 claims 6
- 210000003296 saliva Anatomy 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (8)
1. Uporaba laktoferina ili molekula nukleinske kiseline koja kodira isti, u dijagnozi ili prognozi Alzheimerove bolesti u biološkom uzorku dobivenom od subjekta izabranog od mukoznog tkiva i sline.
2. Postupak za dijagnozu Alzheimerove bolesti kod subjekta koji pokazuje fenokonverziju neurološke bolesti, koji sadrži:
- procjenu razine laktoferina u uzorku sline dobivenom od navedenog subjekta, i
- određivanje da li je navedena razina iznad ili ispod vrijednosti od 6.5 μg/ml, pri čemu je vrijednost ispod 6.5 μg/ml indikativna za Alzheimerovu bolest.
3. Postupak za prognozu Alzheimerove bolesti kod subjekta koji ne pokazuje fenokonverziju neurološke bolesti, koji sadrži:
- procjenu razine laktoferina u uzorku sline dobivenom od navedenog subjekta, i
- određivanje da li je navedena razina iznad ili ispod vrijednosti od 6.5 μg/ml, pri čemu je vrijednost ispod 6.5 μg/ml indikativna za prognozu Alzheimerove bolesti.
4. Postupak za prognozu prema patentnom zahtjevu 3, u kojem je navedena prognoza do vremenskog okvira od devet godina prije nego što navedeni subjekt pokaže fenokonverziju Alzheimerove bolesti.
5. Postupak za prognozu prema patentnom zahtjevu 4, u kojem je navedeni vremenski okvir pet godina.
6. Postupak prema bilo kojem od patentnih zahtjeva 2 do 5, u kojem je navedeni subjekt sisavac.
7. Postupak prema patentnom zahtjevu 6, u kojem je navedeni sisavac čovjek.
8. Sustav za predviđanje razvoja Alzheimerove bolesti kod subjekta koji sadrži sredstva za obradu podataka, pri čemu su sredstva za obradu podataka konfigurirana:
- da procjenjuju razinu laktoferina ili molekula nukleinske kiseline koja kodira istu u uzorku sline;
- da određuju da li je navedeni razina laktoferina ispod unaprijed određene granične vrijednosti; i
- da predvide funkcionalni ishod Alzheimerove bolesti kod subjekta procjenom rezultata prethodnog određivanja.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15195662.0A EP3171174B1 (en) | 2015-11-20 | 2015-11-20 | Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180115T1 true HRP20180115T1 (hr) | 2018-04-06 |
Family
ID=54697475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180115TT HRP20180115T1 (hr) | 2015-11-20 | 2018-01-22 | Laktoferin za uporabu u dijagnozi ili prognozi alzheimerove bolesti |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11422137B2 (hr) |
| EP (2) | EP3171174B1 (hr) |
| JP (1) | JP6991970B2 (hr) |
| KR (1) | KR102579727B1 (hr) |
| CN (1) | CN108431608B (hr) |
| AU (1) | AU2016354981B2 (hr) |
| BR (1) | BR112018010266A2 (hr) |
| CA (1) | CA3005784C (hr) |
| CL (1) | CL2018001343A1 (hr) |
| CO (1) | CO2018006298A2 (hr) |
| CY (1) | CY1119797T1 (hr) |
| DK (1) | DK3171174T3 (hr) |
| EC (1) | ECSP18046355A (hr) |
| ES (1) | ES2657414T3 (hr) |
| HR (1) | HRP20180115T1 (hr) |
| HU (1) | HUE037916T2 (hr) |
| LT (1) | LT3171174T (hr) |
| MD (1) | MD3171174T2 (hr) |
| ME (1) | ME02993B (hr) |
| MX (1) | MX2018006189A (hr) |
| NO (1) | NO3171174T3 (hr) |
| NZ (1) | NZ743563A (hr) |
| PL (2) | PL3171174T3 (hr) |
| PT (1) | PT3171174T (hr) |
| RS (1) | RS56832B1 (hr) |
| RU (1) | RU2745602C2 (hr) |
| SI (1) | SI3171174T1 (hr) |
| WO (1) | WO2017085214A1 (hr) |
| ZA (1) | ZA201804079B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201818373A2 (tr) | 2018-12-03 | 2020-06-22 | T C Erciyes Ueniversitesi | Bağirsak mi̇krobi̇yomundan alzhei̇mer hastaliğinin teşhi̇si̇ i̇çi̇n mi̇ni̇mal bi̇yobeli̇rteçler ve i̇lgi̇li̇ yeni̇ nesi̇l di̇zi̇leme ki̇ti̇ |
| CN112142850A (zh) * | 2019-06-27 | 2020-12-29 | 深圳市卫光生物制品股份有限公司 | 人神经生长因子-乳铁蛋白重组蛋白及用途 |
| CN111415745A (zh) * | 2020-04-03 | 2020-07-14 | 河北医科大学 | 一种雄激素提示老年男性阿尔茨海默病风险的计算方法 |
| CN113049696B (zh) * | 2021-03-04 | 2022-03-18 | 首都医科大学宣武医院 | 一种诊断受试者是否患阿尔茨海默病的代谢产物及其用途 |
| CN113967250A (zh) * | 2021-09-26 | 2022-01-25 | 四川大学 | 乳铁蛋白在预防治疗阿尔兹海默症中的应用 |
| CN114242175A (zh) * | 2021-12-22 | 2022-03-25 | 香港中文大学深圳研究院 | 一种评估脑白质高信号体积的方法及系统 |
| CN115737787B (zh) * | 2022-12-15 | 2024-04-19 | 四川大学 | 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94183A (en) * | 1989-05-05 | 2003-09-17 | Baylor College Medicine | cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE |
| AU2002220029B2 (en) * | 2000-11-14 | 2007-09-06 | Techlab, Inc. | Method for differentiating between irritable bowel syndrome and inflammatory bowel disease using lactoferrin as marker |
| US20030096736A1 (en) | 2001-05-09 | 2003-05-22 | Kruzel Marian L. | Lactoferrin for age related disorders in humans |
| WO2004037073A2 (en) * | 2002-10-25 | 2004-05-06 | Techlab, Inc. | Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel |
| WO2009074331A2 (en) | 2007-12-11 | 2009-06-18 | Julius-Maximilians-Universität Würzburg | Early and differential diagnosis test for alzheimer's disease |
| US20130034863A1 (en) * | 2009-01-23 | 2013-02-07 | Philadelphia Health And Education Corporation | Apparatus and Methods for Detecting Inflammation Using Quantum Dots |
| EP2251032A1 (en) | 2009-05-12 | 2010-11-17 | Nestec S.A. | Lactoferrin and brain health and protection in adults |
| EP3329932A1 (en) | 2009-06-10 | 2018-06-06 | New York University | Immunological targeting of pathological tau proteins |
| US20110236917A1 (en) | 2009-11-17 | 2011-09-29 | Power3 Medical Products, Inc. | Diagnosis of Alzheimer's Disease |
| IN2013CN02996A (hr) * | 2010-10-20 | 2015-08-14 | Eisai R&D Man Co Ltd | |
| WO2013014669A1 (en) * | 2011-07-24 | 2013-01-31 | Carmel-Haifa University Economic Corp. | Lactoferrin fragments and use thereof |
| EP3255435A1 (en) | 2012-04-13 | 2017-12-13 | Oasis Diagnostics Corporation | Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases |
| CN103575903B (zh) * | 2012-08-07 | 2016-01-20 | 中国检验检疫科学研究院 | 一种人乳铁蛋白夹心elisa检测试剂盒及其应用 |
-
2015
- 2015-11-20 LT LTEP15195662.0T patent/LT3171174T/lt unknown
- 2015-11-20 ES ES15195662.0T patent/ES2657414T3/es active Active
- 2015-11-20 PL PL15195662T patent/PL3171174T3/pl unknown
- 2015-11-20 SI SI201530160T patent/SI3171174T1/en unknown
- 2015-11-20 PT PT151956620T patent/PT3171174T/pt unknown
- 2015-11-20 DK DK15195662.0T patent/DK3171174T3/en active
- 2015-11-20 EP EP15195662.0A patent/EP3171174B1/en active Active
- 2015-11-20 ME MEP-2018-12A patent/ME02993B/me unknown
- 2015-11-20 NO NO15195662A patent/NO3171174T3/no unknown
- 2015-11-20 MD MDE20170031T patent/MD3171174T2/ro unknown
- 2015-11-20 RS RS20180039A patent/RS56832B1/sr unknown
- 2015-11-20 HU HUE15195662A patent/HUE037916T2/hu unknown
-
2016
- 2016-11-17 BR BR112018010266A patent/BR112018010266A2/pt active Search and Examination
- 2016-11-17 RU RU2018122111A patent/RU2745602C2/ru not_active Application Discontinuation
- 2016-11-17 CN CN201680076298.1A patent/CN108431608B/zh active Active
- 2016-11-17 NZ NZ743563A patent/NZ743563A/en unknown
- 2016-11-17 CO CONC2018/0006298A patent/CO2018006298A2/es unknown
- 2016-11-17 KR KR1020187017108A patent/KR102579727B1/ko active IP Right Grant
- 2016-11-17 MX MX2018006189A patent/MX2018006189A/es unknown
- 2016-11-17 JP JP2018526624A patent/JP6991970B2/ja active Active
- 2016-11-17 EP EP16809652.7A patent/EP3377909B1/en active Active
- 2016-11-17 CA CA3005784A patent/CA3005784C/en active Active
- 2016-11-17 PL PL16809652T patent/PL3377909T3/pl unknown
- 2016-11-17 WO PCT/EP2016/078060 patent/WO2017085214A1/en active Application Filing
- 2016-11-17 AU AU2016354981A patent/AU2016354981B2/en active Active
- 2016-11-17 US US15/776,462 patent/US11422137B2/en active Active
-
2018
- 2018-01-22 HR HRP20180115TT patent/HRP20180115T1/hr unknown
- 2018-01-23 CY CY20181100083T patent/CY1119797T1/el unknown
- 2018-05-18 CL CL2018001343A patent/CL2018001343A1/es unknown
- 2018-06-18 ZA ZA2018/04079A patent/ZA201804079B/en unknown
- 2018-06-19 EC ECIEPI201846355A patent/ECSP18046355A/es unknown
-
2022
- 2022-07-29 US US17/876,923 patent/US20230081393A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180115T1 (hr) | Laktoferin za uporabu u dijagnozi ili prognozi alzheimerove bolesti | |
| Janssens et al. | A new look at an old dog: Bonn-Oberkassel reconsidered | |
| EP3770603A3 (en) | Assay and method | |
| MX2018001697A (es) | Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores. | |
| BR112017017076A2 (pt) | inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre. | |
| DE602006019475D1 (de) | Verfahren zur mikrorna-identifikation und ihrer anwendungen bei der forschung und menschlichen gesundheit | |
| JP2010503385A5 (hr) | ||
| WO2012125807A3 (en) | Systems and compositions for diagnosing barrett's esophagus and methods of using the same | |
| ATE471512T1 (de) | Verwendung des proteins s100a 12 als marker für kolorektalkarzinom | |
| BR112016028442A2 (pt) | processos para detectar a metilação de citosina de ácido nucleico alvo de interesse e/ou diagnosticar ou monitorar estado de saúde em paciente e kit | |
| ZA201803854B (en) | Biomarkers for prospective determination of risk for development of active tuberculosis | |
| Pacholewska et al. | The transcriptome of equine peripheral blood mononuclear cells | |
| JP2018518725A5 (hr) | ||
| ATE474067T1 (de) | Verfahren zur ermittlung von arzneimittelempfindlichkeit durch analyse von girk-kanal-genen | |
| BR112019023772A2 (pt) | método para detectar doenças induzidas por c. perfringens em animais e kit de diagnóstico | |
| AR099950A1 (es) | Determinación de polimorfismos de un solo nucleótido de utilidad para la predicción de la respuesta a la rasagilina | |
| BR112015021507A2 (pt) | métodos e composições para o diagnóstico de pré-eclampsia | |
| PL406989A1 (pl) | Profil mikro RNA we krwi jako test wykrywania raka płuca | |
| ATE534037T1 (de) | Verwendung des proteins asc als marker für brustkrebs | |
| JP2016520563A5 (hr) | ||
| ES2754384T3 (es) | Métodos para diagnosticar la enfermedad valvular crónica | |
| JP2020178560A5 (hr) | ||
| WO2013010140A3 (en) | Methods of diagnosing cancer | |
| PL422387A1 (pl) | Sposób oznaczania wrażliwości tkanek na insulinę, sposób identyfikacji insulinooporności i/lub określania predyspozycji do zaburzenia z nią związanego, zastosowanie wskaźnika insulinowrażliwości oraz zestawy diagnostyczne i ich zastosowania | |
| JP2020178575A5 (hr) |